Correspondence to letter to the editor 2 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
作者信息
Jeong Seogsong, Kim Won, Park Sang Min
机构信息
Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Biomedical Research Center, Korea University Guro Hospital, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e210-e211. doi: 10.3350/cmh.2024.1175. Epub 2025 Jan 6.
Abstract
摘要
相似文献
1
Correspondence to letter to the editor 2 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e210-e211. doi: 10.3350/cmh.2024.1175. Epub 2025 Jan 6.
2
Correspondence to letter to the editor 1 on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e208-e209. doi: 10.3350/cmh.2024.1171. Epub 2025 Jan 6.
3
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e128-e133. doi: 10.3350/cmh.2024.1008. Epub 2024 Dec 26.
4
Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e125-e127. doi: 10.3350/cmh.2024.1087. Epub 2024 Dec 17.
5
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study".
Clin Mol Hepatol. 2024 Oct;30(4):974-977. doi: 10.3350/cmh.2024.0417. Epub 2024 Jul 4.
6
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7.
7
Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study.
Dig Dis. 2025;43(1):36-45. doi: 10.1159/000541945. Epub 2024 Oct 14.
8
Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan".
Clin Mol Hepatol. 2025 Jan;31(1):e64-e66. doi: 10.3350/cmh.2024.0638. Epub 2024 Aug 19.
9
Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
J Hepatol. 2023 Dec;79(6):1374-1384. doi: 10.1016/j.jhep.2023.08.018. Epub 2023 Aug 28.
10
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
Liver Cancer. 2023 Dec 22;13(4):426-437. doi: 10.1159/000535943. eCollection 2024 Aug.
本文引用的文献
1
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study".
Clin Mol Hepatol. 2025 Apr;31(2):e128-e133. doi: 10.3350/cmh.2024.1008. Epub 2024 Dec 26.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
Liver Cancer. 2023 Dec 22;13(4):426-437. doi: 10.1159/000535943. eCollection 2024 Aug.
3
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7.
4
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
5
Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
EClinicalMedicine. 2023 Oct 28;65:102292. doi: 10.1016/j.eclinm.2023.102292. eCollection 2023 Nov.
6
Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean.
Medicine (Baltimore). 2023 Nov 3;102(44):e35804. doi: 10.1097/MD.0000000000035804.
7
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.
Clin Mol Hepatol. 2023 Oct;29(4):1002-1012. doi: 10.3350/cmh.2023.0205. Epub 2023 Sep 11.
8
Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease.
Gut Liver. 2022 Jul 15;16(4):589-598. doi: 10.5009/gnl210256. Epub 2021 Nov 3.
Zotero 插件